Edition:
United States

Concordia International Corp (CXRX.OQ)

CXRX.OQ on NASDAQ Stock Exchange Global Select Market

0.50USD
20 Apr 2018
Change (% chg)

$0.00 (+0.48%)
Prev Close
$0.50
Open
$0.52
Day's High
$0.52
Day's Low
$0.49
Volume
21,294
Avg. Vol
72,801
52-wk High
$2.10
52-wk Low
$0.45

Chart for

About

No overview information found for .
No analyst recommendations are available for .

Overall

No Ratios Available.

Financials

  CXRX.OQ Industry Sector
P/E (TTM): -- 31.01 33.60
EPS (TTM): -- -- --
ROI: -- 13.60 13.19
ROE: -- 15.26 15.00

BRIEF-Concordia International Reports GAAP Net Loss For Q4 Of $431.8 Mln Included Impairment Charges Of $207.7 Mln

* GAAP NET LOSS FOR Q4 OF $431.8 MILLION INCLUDED IMPAIRMENT CHARGES OF $207.7 MILLION

Mar 08 2018

BRIEF-Concordia International Says UK Competition, Markets Authority Notified Co It Is Closing Investigation Related To Fusidic Acid Eye Drops

* CONCORDIA INTERNATIONAL CORP - UK COMPETITION AND MARKETS AUTHORITY NOTIFIED CO THAT IT IS CLOSING ITS INVESTIGATION RELATED TO FUSIDIC ACID EYE DROPS

Feb 15 2018

BRIEF-Concordia International To Defer Payment Of About $37.5 Mln Interest Due Dec 15

* CONCORDIA INTERNATIONAL CORP - ‍DETERMINED TO DEFER PAYMENT OF APPROXIMATELY $37.5 MILLION OF INTEREST DUE DEC 15 ON 9.5% SENIOR UNSECURED NOTES​

Dec 15 2017

Drug firm Concordia overcharged Britain's health service with 6,000 percent price rise

LONDON Drug company Concordia overcharged Britain's health service millions of pounds for an essential thyroid drug by abusing its position as the only supplier, the country's Competition and Markets Authority said on Tuesday.

Nov 21 2017

UPDATE 1-Drug firm Concordia overcharged Britain's health service with 6,000 pct price rise

LONDON, Nov 21 Drug company Concordia overcharged Britain's health service millions of pounds for an essential thyroid drug by abusing its position as the only supplier, the country's Competition and Markets Authority said on Tuesday.

Nov 21 2017

Britain says Canada's Concordia overcharging health service for thyroid drug

LONDON, Nov 21 Drug company Concordia overcharged Britain's health service millions of pounds for an essential thyroid drug by abusing its position as the only supplier, the country's Competition and Markets Authority said on Tuesday.

Nov 21 2017

BRIEF-Concordia International ‍comments on UK CMA statement of objections related to Liothyronine

* ‍COMMENTS ON CMA STATEMENT OF OBJECTIONS RELATED TO LIOTHYRONINE; SAYS "DO NOT BELIEVE THAT COMPETITION LAW HAS BEEN INFRINGED​"

Nov 21 2017

BRIEF-Concordia International Q3 ‍reported revenue $154.6 mln

* Concordia International announces third quarter 2017 results

Nov 14 2017

Earnings vs. Estimates

No consensus analysis data available.